Corbus Awarded US Patent Covering Lenabasum as Potential CF and Fibrotic Disease Treatment
Corbus Pharmaceuticals has received a patent from the U.S. Patent and Trademark Office covering all compositions that comprise lenabasum...
MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...
Decibel Obtains Exclusive License for ORC-13661 for Prevention of Antibiotic-related Ototoxicity
Decibel Therapeutics received worldwide, exclusive rights to develop and commercialize ORC-13661, Oricula Therapeutics’ investigational...
New Approach Against Antibiotic-resistant Bacteria in CF Patients Shows Promise in Phase 1 Trial
Researchers may have found a new way of treating antibiotic-resistant bacterial infections, specifically Pseudomonas aeruginosa, in the...
Sound Pharmaceuticals to present initial data on the STOP Ototoxicity Study at Cystic Fibrosis Confe
Sound Pharmaceuticals (SPI) is pleased to announce that its recent submission to the upcoming North American Cystic Fibrosis Conference...
Chronic P. Aeruginosa Infection Greatly Raises Risk of Flares in Non-CF Bronchiectasis, Study Shows
People with non-cystic fibrosis (CF) bronchiectasis are at a significantly greater risk of exacerbations if they have chronic infections...
Understanding antibiotic resistance in patients with cystic fibrosis
A defective gene causes thick, sticky mucus to build up in the lungs of patients with cystic fibrosis (CF). There, it traps bacteria,...
#NACFC — Sound Pharmaceuticals to Present Preliminary Data on Ototoxicity Study
Sound Pharmaceuticals (SPI) will present data on the incidence and severity of ototoxicity in cystic fibrosis (CF) patients who received...
MS1819-SD Shows Positive Results for Exocrine Pancreatic Insufficiency in Phase 2a Trial
AzurRx BioPharma, in partnership with Mayoly Spindler, announced that a recent Phase 2a clinical trial testing MS1819-SD as a potential...
